Listed

Zevra Therapeutics, Inc.

ZVRAQ3 FY2026Period ended Sep 30, 2026

Fiscal period
Q3 FY2026
Period end
2026-09-30
Report due by
2026-11-05from the company's last four reports
Margin metric
Operating margin
Status
Locked
Scored against
The 10-Q for the quarter, figures as first reported
Locks
Locked Nov 3, 2026, 17:16 ET

Locked

Forecasts locked Nov 3, 2026, 17:16 ET, when EDGAR accepted Zevra Therapeutics, Inc.'s 10-Q, accession 0001434647-26-000087. Anything saved after that second does not count.

Forecasts

Members with a public profile.

No public forecasts on this target.